• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (69)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Quantitative Review of Data From Randomized Clinical Trials

Christopher O. Phillips, MD, MPH; Amir Kashani, MS, MD; Dennis K. Ko, MD; Gary Francis, MD; Harlan M. Krumholz, MD, SM

Arch Intern Med. 2007;167(18):1930-1936.

Background  We performed a meta-analysis of randomized controlled trials to assess ongoing concerns about the safety profile of combination angiotensin II receptor blockers (ARBs) plus angiotensin-converting enzyme (ACE) inhibitors in symptomatic left ventricular dysfunction.

Methods  MEDLINE (January 1966–December 2006) and Web sites for the National Institute of Health Clinical Trials and the Food and Drug Administration were searched for eligible RCTs that included 500 or more subjects, had a follow-up of 3 months or longer, and reported adverse effects. We used a random effects model to calculate the relative risk (RR) and 95% confidence interval (CI) for the following outcome measures: medication discontinuations because of adverse effects, worsening renal function (an increase in serum creatinine level of > 0.5 mg/dL [to convert to micromoles per liter, multiply by 88.4]), hyperkalemia (serum potassium level > 5.5 mEq/L [to convert to millimoles per liter, multiply by 1]), and symptomatic hypotension.

Results  Four studies (N = 17 337; mean follow-up, 25 months [range, 11-41 months]) were selected. Combination ARB plus ACE inhibitor vs control treatment that included ACE inhibitors was associated with significant increases in medication discontinuations because of adverse effects in patients with chronic heart failure (RR, 1.38 [95% CI, 1.22-1.55]) or in patients with acute myocardial infarction with symptomatic left ventricular dysfunction (RR, 1.17 [95% CI, 1.03-1.34]), and for both conditions there were significant increases in worsening renal function (RR, 2.17 [95% CI, 1.59-2.97] and RR, 1.61 [95% CI, 1.31-1.98], respectively), hyperkalemia (RR, 4.87 [95% CI, 2.39-9.94] and RR, 1.33 [95% CI, 0.90-1.98], respectively; the latter was not significant), and symptomatic hypotension (RR, 1.50 [95% CI, 1.09-2.07], and RR, 1.48 [95% CI, 1.33-3.18], respectively).

Conclusion  Combination ARB plus ACE inhibitor therapy in subjects with symptomatic left ventricular dysfunction was accompanied by marked increases in adverse effects.

Author Affiliations: Department of General Internal Medicine and Section of Hospital Medicine, The Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio (Dr Phillips); Yale University School of Medicine and Yale–New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Connecticut (Drs Kashani and Krumholz); Division of Cardiology, The Cleveland Clinic (Dr Francis); and Division of Cardiology, Schulich Hearth Center, Sunnybrook Health Sciences Centre, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada (Dr Ko).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
Rossignol et al.
Circulation 2012;125:271-279.
ABSTRACT | FULL TEXT  

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis
Harel et al.
BMJ 2012;344:e42-e42.
ABSTRACT | FULL TEXT  

Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme
Becari et al.
Am. J. Physiol. Heart Circ. Physiol. 2011;301:H565-H570.
ABSTRACT | FULL TEXT  

The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis
McAlister et al.
CMAJ 2011;183:655-662.
ABSTRACT | FULL TEXT  

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors
Phillips
CMAJ 2011;183:E309-E311.
FULL TEXT  

Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends
Gullapalli et al.
Ther Adv Cardiovasc Dis 2010;4:359-373.
ABSTRACT  

Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly: Benefits and Limitations
Turgut et al.
CJASN 2010;5:1330-1339.
ABSTRACT | FULL TEXT  

{beta}-Arrestin-Biased Agonism of the Angiotensin Receptor Induced by Mechanical Stress
Rakesh et al.
Sci Signal 2010;3:ra46-ra46.
ABSTRACT | FULL TEXT  

Implications of Recently Published Trials of Blood Pressure-Lowering Drugs in Hypertensive or High-Risk Patients
Staessen et al.
Hypertension 2010;55:819-831.
ABSTRACT | FULL TEXT  

Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir and Rolfe
CJASN 2010;5:531-548.
ABSTRACT | FULL TEXT  

Is therapy of people with chronic kidney disease ONTARGET?
Mann et al.
Nephrol Dial Transplant 2010;25:42-44.
FULL TEXT  

Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure
Anand et al.
Circulation 2009;120:1577-1584.
ABSTRACT | FULL TEXT  

RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice
Pitt
Heart 2009;95:1205-1208.
FULL TEXT  

Effect of Telmisartan on Renal Outcomes: A Randomized Trial
Mann et al.
ANN INTERN MED 2009;151:1-10.
ABSTRACT | FULL TEXT  

Managing cardiovascular and renal risk: the potential of direct renin inhibition
Sever et al.
Journal of Renin-Angiotensin-Aldosterone System 2009;10:65-76.
ABSTRACT  

Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
Navaneethan et al.
CJASN 2009;4:542-551.
ABSTRACT | FULL TEXT  

Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies
Dunn et al.
Nutr Clin Pract 2009;24:60-75.
ABSTRACT | FULL TEXT  

Preventing renal disease progression: Can complete renin-angiotensin-aldosterone blockade work?
SCHREIBER
Cleveland Clinic Journal of Medicine 2008;75:699-704.
FULL TEXT  

ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET
Schindler
Ther Adv Cardiovasc Dis 2008;2:233-248.
ABSTRACT  

Review: The therapeutic role of RAS blockade in chronic heart failure
Werner and Bohm
Ther Adv Cardiovasc Dis 2008;2:167-177.
ABSTRACT  

What's new in hypertension 2007?
Mann
Nephrol Dial Transplant 2008;23:466-470.
FULL TEXT  

Combination ACE-Inhibitor and Angiotensin-Receptor Blocker Therapy: A Review of Safety Data
JWatch General 2007;2007:1-1.
FULL TEXT  

Combination ACE-inhibitor and Angiotensin-Receptor Blocker Therapy: A Review of Safety Data
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT